Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by 4D Molecular Therapeutics, Inc.

< Previous 1 2 Next >
4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis Conference
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT Reports First Quarter 2024 Financial Results and Operational Highlights
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT to Participate in Upcoming Investor Conference
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT Announces Presentations at ARVO 2024 Annual Meeting
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT Reports Full Year 2023 Financial Results and Operational Highlights
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMD
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT to Present Interim 24 Week Data from Randomized Phase 2 PRISM Clinical Trial of 4D-150 in High Treatment Need Wet AMD Patients at Angiogenesis, Exudation, and Degeneration 2024 Conference
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT Reports Third Quarter 2023 Financial Results and Operational Highlights
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Cystic Fibrosis at 2023 NACFC
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT Gains Alignment with FDA on Plan to Lift Clinical Hold on Phase 1/2 INGLAXA Clinical Trial for 4D-310 for Fabry Disease Cardiomyopathy
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 2023 NACFC
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT Receives EMA Priority Medicines (PRIME) Designation for 4D-150 Clinical-Stage Genetic Medicine for Treatment of Wet AMD
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT Appoints Uneek Mehra as Chief Financial and Business Officer
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT Announces First Patient Enrolled in 4D-150 Phase 2 SPECTRA Clinical Trial in DME, and Expansion of 4D-150 Phase 2 Stage in PRISM Clinical Trial in Wet AMD
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4D Molecular Therapeutics Reports Second Quarter 2023 Financial Results and Operational Highlights
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT Presents Additional Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ASRS 2023
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT Completes Enrollment of Phase 2 PRISM Clinical Trial for Intravitreal 4D-150 in Patients with Wet AMD and Reports Interim Safety and Tolerability Data
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
4DMT Presents Positive Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial in Patients with Cystic Fibrosis at the ECFS 46th Annual Meeting
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Tickers FDMT
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.